Novedades

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Investigación

• Japan’s drug shortage crisis: challenges and policy solutions
• Saudi FDA drug approvals and GMP inspections: trend analysis
• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study

General

• Crecimiento de medicamentos genéricos en Brasil y Venezuela
• EMA launches European shortages monitoring platform to tackle persistent medicine shortages
• Penetración de los medicamentos genéricos en México y Brasil
• FDA releases one-year progress report for the Generic Drug Cluster

Novedades

• EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
• EMA recommends approval for teriparatide biosimilar Zandoriah
• FDA approves third interchangeable ranibizumab biosimilar Nufymco
• FDA approves Poherdy (first interchangeable pertuzumab) and Armlupeg (pegfilgrastim) biosimilars

Investigación

• OECD study finds no direct link between advertising rules and biosimilar uptake
• Alcanzar los objetivos ASG en el desarrollo farmacéutico
• What is the future for the US biosimilar interchangeability designation
• Estudios de eficacia clínica en biosimilares: ¿siguen siendo necesarios?

General

• La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares
• Biosimilars approved in the US
• Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
• Biosimilars approved in Europe

• Latin American Forum
• Fármacos complejos no biológicos
• Enfoque por país

• Directrices
• Políticas y legislación
• Informes

• Congresos
• Artículos patrocinados
• Enlaces patrocinados